Related Experiment Videos
A reevaluation of the exclusion criteria used in antidepressant efficacy trials
Michael A Posternak1, Mark Zimmerman, Gabor I Keitner
1Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence 02905, USA. mposternak@lifespan.org
Objective:
Antidepressant efficacy trials use multiple exclusion criteria that are intended primarily to maximize differences between the drug and placebo. These exclusion criteria were implemented prior to having undergone rigorous testing, however, and it is unclear whether they accomplish their intended goal. The authors review the current state of knowledge about treatment response rates in individuals who are typically excluded from antidepressant efficacy trials.
Method:
After reviewing 31 antidepressant efficacy trials published between 1994 and 1998, the authors identified 10 commonly used exclusion criteria. A computerized MEDLINE search and a manual search were used to identify studies evaluating the efficacy of antidepressant medications in populations of subjects typically excluded from antidepressant efficacy trials.
Results:
Three exclusion criteria-short episode duration, mild severity of illness, and positive response during the placebo lead-in phase-are used primarily to reduce placebo response rates. Preliminary evidence suggests that, of those three criteria, only a short episode duration has been associated with less robust differences between drug and placebo response rates. The seven other exclusion criteria, including various psychiatric comorbidities, long duration of illness, medical comorbidity, and prior nonresponse to treatment, are used because individuals who meet those criteria are believed to have lower response rates to somatic therapy. Although such individuals are often found to have lower response rates to somatic therapy, they also appear to have lower response rates to placebo, and there is little evidence to suggest that drug-placebo differences are any less robust in these individuals.
Conclusions:
Many of the standard exclusion criteria currently used in antidepressant efficacy trials may not be achieving their intended goal of maximizing drug-placebo differences. The practice of excluding subjects with particular clinical profiles, which greatly reduces the generalizability of antidepressant efficacy trials, appears to lack empirical support.
Insights
Many common exclusion criteria in antidepressant trials may not enhance drug-placebo differences. Excluding patients with specific profiles reduces generalizability without clear empirical support, questioning trial validity.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Antidepressant efficacy trials commonly employ exclusion criteria to maximize drug-placebo differences.
- The empirical basis and effectiveness of these exclusion criteria are not well-established.
- This review examines treatment response rates in populations typically excluded from efficacy trials.
Purpose of the Study:
- To evaluate whether standard exclusion criteria in antidepressant efficacy trials effectively maximize drug-placebo differences.
- To assess the empirical support for excluding specific patient profiles from clinical trials.
- To determine the impact of exclusion criteria on the generalizability of trial findings.
Main Methods:
- Review of 31 antidepressant efficacy trials published between 1994 and 1998 to identify common exclusion criteria.
- MEDLINE and manual searches to find studies on antidepressant efficacy in excluded populations.
- Analysis of existing literature on treatment response rates in specific patient groups.
Main Results:
- Three criteria (short episode duration, mild illness, positive placebo response) aim to reduce placebo response, but only short episode duration showed reduced drug-placebo differences.
- Seven other criteria (comorbidities, long illness duration, prior nonresponse) are intended to identify patients with lower treatment response.
- However, these excluded groups also show lower placebo response rates, with no clear evidence of diminished drug-placebo differences.
Conclusions:
- Many standard exclusion criteria in antidepressant trials may not achieve their intended goal of maximizing drug-placebo differences.
- Excluding patients with certain clinical profiles reduces trial generalizability without strong empirical justification.
- The current exclusion practices in antidepressant efficacy trials may lack sufficient empirical support.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:25Antidepressant Drugs: Overview
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:30Electroconvulsive Therapy
01:54The Placebo Effect